

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): ~~Peptide~~ A peptide consisting of the peptide sequence

(I) below:

J<sup>1</sup>-J<sup>2</sup>-J<sup>3</sup>-J<sup>4</sup>-J<sup>5</sup>-J<sup>6</sup>-[[Z<sup>7</sup>]] Asp-U<sup>8</sup>-J<sup>9</sup>-J<sup>10</sup>-U<sup>11</sup>-Arg-J<sup>13</sup>-[[J<sup>14</sup>]] Ala-U<sup>15</sup>-Lys-Gly-X<sup>18</sup>-Gly-Thr-J<sup>21</sup>-Glu-J<sup>23</sup>-J<sup>24</sup>-U<sup>25</sup>-J<sup>26</sup>-J<sup>27</sup>-J<sup>28</sup>-U<sup>29</sup>-J<sup>30</sup>-J<sup>31</sup>-Arg-J<sup>33</sup>-J<sup>34</sup>-J<sup>35</sup>-J<sup>36</sup>-B<sup>37</sup>-[[J<sup>38</sup>]] Gln-J<sup>39</sup>-U<sup>40</sup>-J<sup>41</sup>-J<sup>42</sup>-J<sup>43</sup>-U<sup>44</sup>-J<sup>45</sup>-J<sup>46</sup>-J<sup>47</sup>-J<sup>48</sup>-J<sup>49</sup>-Arg-J<sup>51</sup>-U<sup>52</sup>-J<sup>53</sup>-J<sup>54</sup>-Asp-U<sup>56</sup>-Lys-Ser-Z<sup>59</sup>-Leu-J<sup>61</sup>-[[J<sup>62</sup>]] Gly-J<sup>63</sup>-J<sup>64</sup>-Z<sup>65</sup>-J<sup>66</sup>-J<sup>67</sup>-U<sup>68</sup>-J<sup>69</sup>-J<sup>70</sup>-U<sup>72</sup>-J<sup>73</sup>-J<sup>74</sup>-[[J<sup>75</sup>]] Ser (I; SEQ ID NO: 15),

in which J, Z, U, X and B represent the following amino acids such that:

- the amino acids J are selected chosen, independently of one another, from ~~natural amino acids or derivatives thereof~~, such that at least 50% of ~~them~~ the amino acids J are polar residues chosen selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Lys, Orn, Pro, Ser, Thr and Tyr,

— ~~the amino acids U are chosen from Ala, Cys, Gly, Ile, Leu, Met, Phe, Trp, Tyr and Val,~~

- the amino acid X<sup>18</sup> is selected chosen, independently of the other amino acids at the other positions of the sequence (I), from the group consisting of Ala, Asn, Cys, Gln, Gly, His, Ile, Leu, Met, Phe, Ser, Thr, Trp, Tyr and Val,

— ~~the amino acid B<sup>37</sup> is chosen, independently of the other amino acids of the sequence, from Arg, Ala, Cys, Gly, Ile, Leu, Met, Phe, Trp, Tyr and Val,~~

— ~~the amino acid Z<sup>7</sup> is chosen, independently of the other amino acids of the sequence, from Asp and Glu,~~

- the amino acids Z<sup>59</sup> and Z<sup>65</sup> are selected chosen, independently of one another, from the group consisting of Glu, Asp, Lys [or] and Arg,

- the amino acids U and B of the sequence (I) are selected according to one of combinations from a) to j) of table 1 below:

Table 1

	<u>U<sup>8</sup></u>	<u>U<sup>11</sup></u>	<u>U<sup>15</sup></u>	<u>U<sup>25</sup></u>	<u>U<sup>29</sup></u>	<u>B<sup>37</sup></u>	<u>U<sup>40</sup></u>	<u>U<sup>44</sup></u>	<u>U<sup>52</sup></u>	<u>U<sup>56</sup></u>	<u>U<sup>68</sup></u>	<u>U<sup>72</sup></u>
a)	<u>Val</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Tyr</u>	<u>Leu</u>	<u>Leu</u>	<u>Val</u>	<u>Leu</u>
b)	<u>Ala</u>	<u>Ile</u>	<u>Ile</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Tyr</u>	<u>Leu</u>	<u>Leu</u>	<u>Ile</u>	<u>Leu</u>
c)	<u>Ala</u>	<u>Ile</u>	<u>Ile</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Tyr</u>	<u>Leu</u>	<u>Leu</u>	<u>Met</u>	<u>Val</u>
d)	<u>Ala</u>	<u>Leu</u>	<u>Met</u>	<u>Leu</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Tyr</u>	<u>Leu</u>	<u>Leu</u>	<u>Ile</u>	<u>Met</u>
e)	<u>Ala</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Ile</u>	<u>Arg</u>	<u>Val</u>	<u>Tyr</u>	<u>Leu</u>	<u>Leu</u>	<u>Ile</u>	<u>Met</u>
f)	<u>Ala</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Ile</u>	<u>Arg</u>	<u>Ile</u>	<u>Phe</u>	<u>Leu</u>	<u>Leu</u>	<u>Ile</u>	<u>Met</u>
g)	<u>Ala</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Val</u>	<u>Arg</u>	<u>Ile</u>	<u>Phe</u>	<u>Leu</u>	<u>Leu</u>	<u>Ile</u>	<u>Phe</u>
h)	<u>Val</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Phe</u>	<u>Leu</u>	<u>Leu</u>	<u>Ile</u>	<u>Met</u>
i)	<u>Ala</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Phe</u>	<u>Leu</u>	<u>Leu</u>	<u>Ile</u>	<u>Met</u>
j)	<u>Ala</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Tyr</u>	<u>Leu</u>	<u>Leu</u>	<u>Ala</u>	<u>Ala</u>
k)	<u>Val</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Tyr</u>	<u>Leu</u>	<u>Leu</u>	<u>Val</u>	<u>Leu</u>
l)	<u>Val</u>	<u>Leu</u>	<u>Met</u>	<u>Ile</u>	<u>Leu</u>	<u>Arg</u>	<u>Ile</u>	<u>Phe</u>	<u>Leu</u>	<u>Leu</u>	<u>Val</u>	<u>Leu</u>

the superscripts of J, Z, U, X and B representing represent the position of these the J, Z, U, X and B amino acids in said sequence (I).

Claim 2 (Currently Amended): Peptide The peptide according to Claim 1, in which the amino acids J are selected chosen, independently of one another, from the group consisting of Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val, such that at least 50% of them the amino acids J are polar residues chosen selected from the group consisting of Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Pro, Ser and Thr.

Claim 3 (Cancelled):

Claim 4 (Currently Amended): A peptide Peptide consisting of a sequence chosen selected from the sequences of SEQ ID No. 1 to SEQ ID No. 10.

Claim 5 (Currently Amended): A peptide Peptide consisting of the sequence of SEQ ID No. 1.

Claim 6 (Currently Amended): Peptide The peptide according to Claim 1, wherein a tripeptide sequence is linked to the N-terminal end of the sequence (I), wherein said tripeptide sequence is selected from the group consisting of Gly-Ser-Cys-, Gly-Ser-Thr-, Gly-Ser-Pro-, Gly-Ser-Ser-, Gly-Ser-Gly-, and Gly-Ser-Gln-.

Claim 7 (Currently Amended): Peptide The peptide according to Claim 1, wherein a tetrapeptide sequence is linked to the N-terminal end of the sequence (I), wherein said tetrapeptide sequence is selected from the group consisting of Gly-Ser-Gly-Cys- (SEQ ID NO: 17), Gly-Cys-Gly-Ser- (SEQ ID NO: 18), Gly-Ser-Gly-Ser- (SEQ ID NO: 19), and Gly-Cys-Gly-Cys- (SEQ ID NO: 20).

Claim 8 (Currently Amended): Peptide A peptide consisting of the sequence of SEQ ID No. 11 or SEQ ID No. 12.

Claim 9 (Currently Amended): Peptide A peptide consisting of the sequence of SEQ ID No. 13 or SEQ ID No. 14.

Claim 10 (Withdrawn/Currently Amended): ~~Process A process~~ for producing a peptide according to Claim 1, said process comprising solid-phase chemical synthesis of said peptide.

Claim 11 (Withdrawn/Currently Amended): ~~Process A process~~ for producing a peptide according to Claim 1, in culture, said process comprising:

- a) preparing a cDNA comprising a basic sequence encoding said peptide,
- b) inserting said cDNA into a suitable expression vector,
- c) transforming a suitable host cell with said vector into which the cDNA has been inserted, for replication of the plasmid,
- d) producing said peptide by translation of said cDNA in said host cell, and
- e) recovering the synthesized peptide.

Claim 12 (Withdrawn/Currently Amended): ~~Process The process~~ according to Claim 11, in which the vector is a plasmid.

Claim 13 (Withdrawn/Currently Amended): ~~Process The process~~ according to Claim 11, in which the vector is the vector pGEX-2T.

Claim 14 (Withdrawn/Currently Amended): ~~Process The process~~ according to Claim 11, in which the host cell is *E. coli*.

Claim 15 (Currently Amended): ~~Chemical~~ A ~~chemical~~ assembly with affinity for a phospholipid, comprising at least two peptides as defined in Claim 1, which may be identical or different, said peptides being linked to one another.

Claim 16 (Currently Amended): ~~Chemical~~ The ~~chemical~~ assembly according to Claim 15, in which at least one of the peptides is a peptide consisting of a sequence selected ~~chosen~~ from the sequences of SEQ ID No. 1 to SEQ ID No. 10.

Claim 17 (Withdrawn): A method for covering a biomaterial comprising contacting said biomaterial with a peptide according to Claim 1.

Claim 18 (Withdrawn): A method for producing a filter for trapping activated circulating blood cells immobilizing a peptide according to Claim 1 said filter.

Claim 19 (Currently Amended): ~~Labelling~~ A ~~labeling~~ compound comprising a peptide as defined in Claim 1, coupled to a ~~labelling~~ labeling molecule or to nanoparticles that are dense in electron microscopy.

Claim 20 (Currently Amended): ~~Labelling~~ A ~~labeling~~ compound comprising ~~an~~ a ~~chemical~~ assembly as defined in Claim 15, coupled to a ~~labelling~~ labeling molecule or to nanoparticles that are dense in electron microscopy, wherein the labeling molecule or the nanoparticles label the chemical assembly.

Claim 21 (Currently Amended): ~~Compound~~ The ~~labeling~~ compound according to Claim 19, in which the ~~labelling~~ labeling molecule is a fluorescent molecule.

Claim 22 (Currently Amended): Compound The labeling compound according to Claim 19, in which the labelling labeling molecule consists of one of the partners of the avidin-biotin system.

Claim 23 (Currently Amended): Compound The labeling compound according to Claim 19, in which the labelling labeling molecule is a radio element.

Claim 24 (Currently Amended): Compound The labeling compound according to Claim 19, in which the labelling labeling molecule is a contrast agent in magnetic resonance imaging.

Claim 25 (Currently Amended): Compound The labeling compound according to Claim 19, in which the labelling labeling molecule is technetium.

Claim 26 (Currently Amended): Compound The labeling compound according to Claim 19, in which the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 27 (Currently Amended): Diagnostic A diagnostic kit comprising a compound according to Claim 19.

Claim 28 (Currently Amended): Diagnostic A diagnostic kit according to Claim 27, also comprising a suitable reagent for detecting said labelling labeling molecule.

Claim 29 (Currently Amended): A kit ~~Kit~~ for analysing and detecting negative charges at the surface of cells, ~~characterized in that it comprises~~ comprising a peptide according to Claim 1.

Claim 30 (Currently Amended): A kit ~~Kit~~ for analysing and detecting negative charges at the surface of cells, ~~characterized in that it comprises~~ comprising an a chemical assembly according to Claim 15.

Claim 31 (Currently Amended): A kit ~~Kit~~ for analysing analyzing and detecting microvesicles in the blood, ~~characterized in that it comprises~~ comprising a peptide according to Claim 1.

Claim 32 (Currently Amended): A kit ~~Kit~~ for analysing analyzing and detecting microvesicles in the blood, ~~characterized in that it comprises~~ comprising an a chemical assembly according to Claim 15.

Claim 33 (Currently Amended): The kit ~~Kit~~ according to Claim 29, in which the peptide is coupled to a label.

Claim 34 (Currently Amended): The kit ~~Kit~~ according to Claim 30, in which the assembly is coupled to a label.

Claim 35 (Currently Amended): Filter A filter for dialysing dialyzing activated circulating blood cells, said filter ~~being characterized in that it comprises~~ a peptide according to Claim 1.

Claim 36 (Currently Amended): A peptide Peptide comprising the peptide according to Claim 4, wherein and a tripeptide sequence which is linked to the N-terminal end of the peptide according to Claim 4 sequence (I), wherein said tripeptide sequence is selected from the group consisting of Gly-Ser-Cys-, Gly-Ser-Thr-, Gly-Ser-Pro-, Gly-Ser-Ser-, Gly-Ser-Gly-, and Gly-Ser-Gln-.

Claim 37 (Currently Amended): A peptide Peptide comprising the peptide according to Claim 4, wherein and a tetrapeptide sequence which is linked to the N-terminal end of the peptide according to Claim 4 sequence (I), wherein said tetrapeptide sequence is selected from the group consisting of Gly-Ser-Gly-Cys-, Gly-Cys-Gly-Ser-, Gly-Ser-Gly-Ser-, Gly-Cys-Gly-Cys- or Gly-Cys-Gly-Ser-.

Claim 38 (Currently Amended): A peptide Peptide comprising the peptide according to Claim 5, wherein and a tripeptide sequence which is linked to the N-terminal end of the the peptide according to Claim 5 sequence (I), wherein said tripeptide sequence is selected from the group consisting of Gly-Ser-Cys-, Gly-Ser-Thr-, Gly-Ser-Pro-, Gly-Ser-Ser-, Gly-Ser-Gly-, and Gly-Ser-Gln-.

Claim 39 (Currently Amended): A peptide Peptide comprising the peptide according to Claim 5, wherein and a tetrapeptide sequence which is linked to the N-terminal end of the the peptide according to Claim 5 sequence (I), wherein said tetrapeptide sequence is selected from the group consisting of Gly-Ser-Gly-Cys-, Gly-Cys-Gly-Ser-, Gly-Ser-Gly-Ser-, Gly-Cys-Gly-Cys- or Gly-Cys-Gly-Ser-.

Claim 40 (Currently Amended): Labelling A labeling compound comprising an a chemical assembly as defined in Claim 16, coupled to a labelling labeling molecule or to nanoparticles that are dense in electron microscopy, wherein the labeling molecule or the nanoparticles label the chemical assembly.

Claim 41 (Currently Amended): Compound The labeling compound according to Claim 40, in which the labelling labeling molecule is a fluorescent molecule.

Claim 42 (Currently Amended): Compound The labeling compound according to Claim 40, in which the labelling labeling molecule consists of one of the partners of the avidin-biotin system.

Claim 43 (Currently Amended): Compound The labeling compound according to Claim 40, in which the labelling labeling molecule is a radio element.

Claim 44 (Currently Amended): Compound The labeling compound according to Claim 40, in which the labelling labeling molecule is a contrast agent in magnetic resonance imaging.

Claim 45 (Currently Amended): Compound The labeling compound according to Claim 40, in which the labelling labeling molecule is technetium.

Claim 46 (Currently Amended): Compound The labeling compound according to Claim 40, in which the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 47 (Currently Amended): ~~Diagnostic~~ A diagnostic kit comprising a compound according to Claim 40.

Claim 48 (Currently Amended): ~~Diagnostic~~ The diagnostic kit according to Claim 47, also comprising a suitable reagent for detecting said ~~labelling~~ labeling molecule.

Claim 49 (Currently Amended): A kit ~~Kit~~ for analysing and detecting negative charges at the surface of cells, ~~characterized in that it comprises~~ comprising a chemical an assembly according to Claim 16.

Claim 50 (Currently Amended): A kit ~~Kit~~ for analysing and detecting microvesicules in the blood, ~~characterized in that it comprises~~ comprising a chemical an assembly according to Claim 16.

Claim 51 (Currently Amended): The kit ~~Kit~~ according to Claim 50, in which the chemical assembly is coupled to a label.

Claim 52 (Currently Amended): The labeling compound ~~Compound~~ according to Claim 20, in which the ~~labelling~~ labeling molecule is a fluorescent molecule.

Claim 53 (Currently Amended): The labeling compound ~~Compound~~ according to Claim 20, in which the ~~labelling~~ labeling molecule consists of one of the partners of the avidin-biotin system.

Claim 54 (Currently Amended): The labeling compound according to Claim 20, in which the labelling labeling molecule is a radio element.

Claim 55 (Currently Amended): The labeling compound according to Claim 20, in which the labelling labeling molecule is a contrast agent in magnetic resonance imaging.

Claim 56 (Currently Amended): The labeling compound according to Claim 20, in which the labelling labeling molecule is technetium.

Claim 57 (Currently Amended): The labeling compound according to Claim 20, in which the nanoparticles that are dense in electron microscopy are gold nanoparticles.

Claim 58 (Currently Amended): Diagnostic A diagnostic kit comprising a labeling compound according to Claim 20.

Claim 59 (Currently Amended): The diagnostic kit according to Claim 58, also comprising a suitable reagent for detecting said labelling labeling molecule.

Claim 60 (Currently Amended): The kit Kit according to Claim 31, in which the peptide is coupled to a label.

Claim 61 (Currently Amended): The kit Kit according to Claim 32, in which the assembly is coupled to a label.